Nature Communications (Jul 2017)
Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα
- Liqun Chen,
- Alexander E. Aleshin,
- Gulimiran Alitongbieke,
- Yuqi Zhou,
- Xindao Zhang,
- Xiaohong Ye,
- Mengjie Hu,
- Gaoang Ren,
- Ziwen Chen,
- Yue Ma,
- Duo Zhang,
- Shuai Liu,
- Weiwei Gao,
- Lijun Cai,
- Lingjuan Wu,
- Zhiping Zeng,
- Fuquan Jiang,
- Jie Liu,
- Hu Zhou,
- Gregory Cadwell,
- Robert C. Liddington,
- Ying Su,
- Xiao-kun Zhang
Affiliations
- Liqun Chen
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Alexander E. Aleshin
- Sanford Burnham Prebys Medical Discovery Institute
- Gulimiran Alitongbieke
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Yuqi Zhou
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Xindao Zhang
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Xiaohong Ye
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Mengjie Hu
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Gaoang Ren
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Ziwen Chen
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Yue Ma
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Duo Zhang
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Shuai Liu
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Weiwei Gao
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Lijun Cai
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Lingjuan Wu
- College of Biological Science and Engineering, Fuzhou University
- Zhiping Zeng
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Fuquan Jiang
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Jie Liu
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Hu Zhou
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Gregory Cadwell
- Sanford Burnham Prebys Medical Discovery Institute
- Robert C. Liddington
- Sanford Burnham Prebys Medical Discovery Institute
- Ying Su
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- Xiao-kun Zhang
- School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University
- DOI
- https://doi.org/10.1038/ncomms16066
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
The transcription factor retinoid X receptor-alpha (RXRα) can also form homotetramers. Here the authors show that the anti-cancer agent K-80003 selectively inhibits the nongenomic action of N-terminally-cleaved RXRα in tumour cells by stabilizing its tetramerization but not that of full-length RXRα.
